Driving in the melanoma landscape.
The melanoma landscape is rapidly evolving. The melanoma oncologists have now the first successful targets for therapy that have a genetic base--albeit in rare forms of the malignancy. Once melanoma becomes part of the Cancer Genome Atlas consortium, a comprehensive map of genetic changes will be established to point the field to true drivers of the disease that will become new targets for therapy. The same abnormalities will also serve as biomarkers for diagnosis, prognosis and therapy follow-up. Melanomas as a group are heterogeneous as are tumor cells within one lesion. New strategies will move towards individualized therapies and combination therapies to target all cells within a tumor.
Herlyn
Meenhard
M
The Wistar Institute, Philadelphia, PA 19104, USA. herlynm@wistar.org
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019070:Cell Lineage; D016503:Drug Delivery Systems; D015195:Drug Design; D016326:Extracellular Matrix Proteins / Q000502:physiology; D005544:Forecasting; D016147:Genes, Tumor Suppressor; D006801:Humans; D006863:Hydrogen-Ion Concentration; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D035683:MicroRNAs / Q000502:physiology; D009154:Mutation; D009363:Neoplasm Proteins / Q000235:genetics / Q000502:physiology; D009857:Oncogenes; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D012878:Skin Neoplasms / Q000473:pathology; D019139:Tumor Escape
D000970:Antineoplastic Agents; D016326:Extracellular Matrix Proteins; D036341:Intercellular Signaling Peptides and Proteins; D035683:MicroRNAs; D009363:Neoplasm Proteins